At a glance
| Product | Lipfendra |
|---|---|
| Target | PCSK9 |
| Route | Oral tablet |
| FDA approval | July 2026 |
| Indication | Adult hypercholesterolemia, including HeFH |
Overview
Marketed as Lipfendra, enlicitide represents an oral approach to a target previously addressed principally through injectable therapies. Its approval is for LDL-cholesterol reduction alongside diet and exercise in adults. The CORALreef program demonstrated large lipid reductions, including in patients already receiving other lipid-lowering care. However, a trial whose primary endpoint is LDL change does not by itself prove a specific reduction in heart attacks or strokes for this molecule. The catalog therefore distinguishes established LDL-lowering efficacy from the separate question of drug-specific cardiovascular-outcome evidence.
How it works
PCSK9 normally promotes degradation of LDL receptors after they bind circulating LDL particles. Enlicitide blocks the interaction between PCSK9 and the LDL receptor, allowing more receptors to return to the liver-cell surface and remove LDL from blood. Its macrocyclic peptide design and oral formulation make delivery possible despite the absorption challenges typical of peptides. Food-related administration requirements are formulation-specific.
Approved scope
Lipfendra is approved as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The indication is not weight loss and does not establish pediatric use.
Supporting sources [1]
CORALreef Lipids
The randomized trial included 2,909 participants in its intention-to-treat population. At twenty-four weeks, enlicitide produced an adjusted LDL-C reduction about 55.8 percentage points greater than placebo, with reductions maintained at the later study assessment.
Supporting sources [2]
Lipid endpoints and clinical outcomes
Lower LDL-C is a well-established therapeutic target, but this trial primarily measured lipids. The label discusses cardiovascular-outcome evidence for statins and monoclonal-antibody PCSK9 inhibitors; that should not be rewritten as a completed enlicitide-specific cardiovascular-outcome trial.
Adverse effects and remaining questions
Overall adverse-event frequencies were similar to placebo in the major hypercholesterolemia trial. Diarrhea and dizziness were the most common label-listed adverse reactions in the HeFH study. Human pregnancy and lactation data are limited, and the label addresses potential fetal concerns from cholesterol lowering.
Supporting sources [1]
How follow-up is judged
Response is assessed with LDL-C and the person’s overall lipid-management plan. An oral route may alter treatment preferences, but it does not make enlicitide interchangeable with statins, antibody PCSK9 inhibitors or other lipid therapies on a milligram basis.
Supporting sources [1]
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Oral macrocyclic peptide PCSK9 inhibitor.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- FDA: Lipfendra prescribing information, July 2026 ↗Regulatory source · Checked 2026-10-27
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. ↗Original research · Checked 2026-10-27